Monaco Sara E, Rodriguez Erika F, Mahaffey Alyssa L, Dacic Sanja
From the Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA.
Am J Clin Pathol. 2016 Jan;145(1):55-61. doi: 10.1093/ajcp/aqv013.
The FGFR1 gene can be amplified in squamous cell carcinoma of the lung (SqCC). The aim of this study was to compare FGFR1 status with stage and matched primaries with metastases.
Cases with FGFR1 fluorescence in situ hybridization (FISH) testing performed from 2000 to 2013 were evaluated for amplification status and clinicopathologic features.
Of the 336 cases tested by FGFR1 FISH, 52 (15%) were positive for amplification. Eight (13%) of 60 N0 cases and eight (17%) of 46 N1 or N2 cases were amplified, with no statistically significant difference. Of the 24 cases with matched primary and metastatic tumors, 22 (92%) were synchronous and one (4%) had discordant amplification.
Frequency of FGFR1 amplification is similar in SqCC with and without lymph node metastases, but status in metastatic sites may be discordant from the primary in a small subset of cases, which may affect the decision to perform testing of metastatic SqCCs.
FGFR1基因可在肺鳞状细胞癌（SqCC）中发生扩增。本研究旨在比较FGFR1状态与分期以及配对的原发性肿瘤和转移灶情况。
对2000年至2013年进行FGFR1荧光原位杂交（FISH）检测的病例评估其扩增状态和临床病理特征。
在336例接受FGFR1 FISH检测的病例中，52例（15%）扩增呈阳性。60例N0病例中有8例（13%）扩增，46例N1或N2病例中有8例（17%）扩增，差异无统计学意义。在24例配对的原发性肿瘤和转移瘤病例中，22例（92%）为同步性，1例（4%）扩增情况不一致。
FGFR1扩增频率在有或无淋巴结转移的SqCC中相似，但在一小部分病例中转移灶的状态可能与原发性肿瘤不一致，这可能会影响对转移性SqCC进行检测的决策。
